VKTX Stock Recent News
VKTX LATEST HEADLINES
Eli Lilly (LLY -1.24%) and Viking Therapeutics (VKTX -0.12%) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period.
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
Where can you find the next monster stocks? Check out the biotech space.
Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a pair of pre-revenue businesses with price targets that are miles above their current stock prices.
Any investor who owned Viking Therapeutics (VKTX -0.23%) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year and lower to the tune of 68% from their early 2024 high after soaring in 2023.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $32.07, representing a +1.39% change from its previous close.
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO , July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025.
If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high and try to get in on the momentum, or you could look for bargains among stocks that have suffered in recent times.
Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.